7331 - 7340 of 9034 Results
Title
Year
- A Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)2018RESTRICTEDTitle: A Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 90Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.90.15_supplement.p5.068Citation Count: 0
-
OPENTitle: Chalcones and Five-Membered Heterocyclic Isosteres Bind to Alpha Synuclein Fibrils in VitroJournal Name: ACS OmegaPublisher: American Chemical Society (ACS)Vol: 3Issue #: 4Start Page: 4486End Page: 4493Publication Date:Open Access(OA) Status: OPENLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1021/acsomega.7b01897Best OA location URL: https://doi.org/10.1021/acsomega.7b01897Citation Count: 41
-
OPENTitle: Mitochondrial import stress and PINK1-mediated mitophagy: the role of the PINK1-TOMM-TIMM23 supercomplexJournal Name: AutophagyPublisher: Informa UK LimitedVol: 20Issue #: 8Start Page: 1903End Page: 1905Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1080/15548627.2024.2340399Best OA location URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11262206/pdf/KAUP_20_2340399.pdfCitation Count: 15
-
OPENTitle: Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease PatientsJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 9Issue #:Start Page: 38End Page: 38Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2017.00038Best OA location URL: https://doi.org/10.3389/fnagi.2017.00038Citation Count: 63
-
OPENTitle: RIC3 variants are not associated with Parkinson's disease in French-Canadians and FrenchJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 53Issue #:Start Page: 194.e9End Page: 194.e11Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2017.01.005Best OA location URL: https://doi.org/10.1016/j.neurobiolaging.2017.01.005Citation Count: 10
- Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum2016RESTRICTEDTitle: Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrumJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 46Issue #:Start Page: 32End Page: 42Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2016.06.003Citation Count: 26
-
OPENTitle: β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s diseaseJournal Name: SciencePublisher: American Association for the Advancement of Science (AAAS)Vol: 357Issue #: 6354Start Page: 891End Page: 898Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1126/science.aaf3934Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/5761666Citation Count: 435
- Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics2005RESTRICTEDTitle: Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinicsJournal Name: Movement DisordersPublisher: WileyVol: 21Issue #: 4Start Page: 519End Page: 23Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.20751Citation Count: 0
-
OPENTitle: A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s DiseaseJournal Name: Parkinson's DiseasePublisher: WileyVol: 2012Issue #:Start Page: 1End Page: 12Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1155/2012/364684Best OA location URL: https://downloads.hindawi.com/journals/pd/2012/364684.pdfCitation Count: 17
- Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats2018RESTRICTEDTitle: Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian RatsJournal Name: Neurochemical ResearchPublisher: Springer Science and Business Media LLCVol: 43Issue #: 5Start Page: 1035End Page: 1046Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s11064-018-2514-yCitation Count: 14